The Rockefeller University

New Horizons Diagnostics Corporation

Other

Contrafect Corporation

Siga Pharmaceuticals, Inc.

Cornell University

Emory University

Oregon State University

The Rockfeller University

Emery University

New Horizons Diagnostic, Corp

New Horizon Diagnostics Corporation

Astex Pharmaceuticals, Inc.

Bernstein, David

Fischetti, Vincent A.

Vincent A Fischetti

Lawrence J Loomis

Raymond Schuch

Chad Euler

Daniel Craig Nelson

Daniel Gilmer

Jonathan Schmitz

Anu Daniel

Robert C Nowinski

Ambrose Cheung

Debra E Bessen

Assaf Raz

Olaf Schneewind

Gregory Resch

June Rothman Scott

Rolf Lood

Vijaykumar Pancholi

Pauline Yoong

Benjamin Winer

Claudia Rocha

Dennis E Hruby

David J Bearss

Hariprasad Vankayalapati

Yong Xu

Kevin P Campbell

David T Bernstein

Gianni Pozzi

Jasna Rakonjac

Anura Rambukkana

Timothy Vartanian

Kareem Rashid Rumah

Stephen Whitehead

Sherry Kan

Aldis Darzins

John Robbins

Charles Erec Stabbins

Qi Cheng

Sung Lee

Vijay Pancholi

Jutta M Loeffler

Qiong Wang

David Bernstein

Dave Bearss

Charles Erec Stebbins

Jutta Loeffler

The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistantand VISA.

Chimeric bacteriophage lysin with activity againstbacteria

Provided are compositions and methods for use in selectively killing one or more ofand. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more oforbacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. Diagnostic approaches are also included by contacting a sample obtained or derived from an animal, with a recombinant polypeptide, and detecting binding of the polypeptide to bacteria in the sample if said bacteria that are bound to the polypeptide are present in the sample. The polypeptide may thus be detectably labeled to produce a detectable signal.

Compositions and methods comprising lysin PlyCP025 and derivatives thereof

lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization usinglysin polypeptides.

Acinetobacter lysins

The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, includingand, and related conditions. The invention provides compositions and methods incorporating and utilizingderived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

bacteriophage lysins for detection and treatment of gram positive bacteria

lysins for detection and treatment of gram positive bacteria

The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant(MRSA) and vancomycin intermediate(VISA).

Chimeric bacteriophage lysin with activity against staphylococci bacteria

The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.

Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria

The present invention provides isolated dimeric-specific phage lysins having two-specific phage lysin monomers covalently linked to each other, and having killing activity against one or morebacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.

Dimeric bacteriophage lysins

The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistantand VISA.

[object Object]

The invention provides epsilon toxin (ETX) produced bytype B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin-logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).

Methods to protect against and treat multiple sclerosis

Growing community of inventors

West Hempstead, NY, United States of America

Vincent A Fischetti